The top executives of Moderna, Akamai, and FMC just bought stock on the open market. All three shares are in the red for 2025 ...

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Mergers and acquisitions grabbed the spotlight in the biotech sector this week after Jazz Pharmaceuticals announced an ...

Moderna shares experienced a significant surge in trading on Thursday, posting a 5.58% gain in European markets and an impressive jump of up to 16% on the NASDAQ. This remarkable performance was ...

Moderna's CEO Buys MRNA Stock Last night, two purchases of Moderna's stock by a firm controlled by MRNA CEO Stephane Bancel were reported. Bancel's company, called Boston Biotech Ventures ...

And the company isn't done. CEO Stéphane Bancel says that the goal is to eliminate close to $1 billion in costs by the end of ...

But in 2025, Moderna aims to reduce cash cost expenses by $1 billion, CEO Stéphane Bancel said at the J.P. Morgan Healthcare Conference in January. The company will report its 2024 full-year ...

A German court ruled that BioNTech (BNTX) and Pfizer (PFE) have to pay Moderna damages because they infringed on Moderna ...